Praxis Precision Medicines Inc.
Praxis Precision Medicines Announces CNS Drug Development Collaboration and Reports Preliminary Positive Trial Results
Summary
Praxis Precision Medicines, Inc. announced on January 4, 2024, an exclusive collaboration and license agreement with Tenacia Biotechnology for the development and commercialization of ulixacaltamide in Greater China. Additionally, Praxis reported preliminary positive results from a Phase 2a study of PRAX-628, indicating drug activity. The company also disclosed preliminary financial information, showing cash and cash equivalents of approximately $81.3 million as of December 31, 2023.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement